Tisotumab vedotin
Tivdak (tisotumab vedotin) is an antibody pharmaceutical. Tisotumab vedotin was first approved as Tivdak on 2021-09-20. The pharmaceutical is active against tissue factor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Tivdak
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tisotumab vedotin
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Tivdak | tisotumab vedotin-tftv | Seagen Inc. | N-761208 RX | 2021-09-20 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tivdak | Biologic Licensing Application | 2021-09-21 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uterine cervical neoplasms | D002583 | 3 | 5 | 1 | — | — | 6 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 4 | — | — | — | 4 |
| Non-small-cell lung carcinoma | D002289 | 2 | 4 | — | — | — | 4 | ||
| Squamous cell carcinoma of head and neck | D000077195 | 1 | 3 | — | — | — | 3 | ||
| Prostatic neoplasms | D011471 | C61 | 2 | 3 | — | — | — | 3 | |
| Endometrial neoplasms | D016889 | EFO_0004230 | 2 | 3 | — | — | — | 3 | |
| Esophageal neoplasms | D004938 | C15 | 2 | 3 | — | — | — | 3 | |
| Urinary bladder neoplasms | D001749 | C67 | 2 | 3 | — | — | — | 3 | |
| Neoplasms | D009369 | C80 | 1 | 1 | — | — | — | 1 | |
| Fallopian tube neoplasms | D005185 | — | 1 | — | — | — | 1 | ||
| Peritoneal neoplasms | D010534 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TISOTUMAB VEDOTIN |
| INN | tisotumab vedotin |
| Description | Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. It is administered by infusion into a vein.
|
| Classification | Antibody |
| Drug class | synthetic analogs of the dolastatin series; monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1418731-10-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297841 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB16732 |
| UNII ID | T41737F88A (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
Tivdak - Seagen Inc.
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 204 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tivdak
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
26 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more